To understand the factors controlling expression of the cGMP phosphodiesterase type 6 (PDE6) genes, we have characterized the promoter of the human PDE6A gene that encodes the catalytic ␣-subunit. In vivo DNase I hypersensitivity assays revealed two sites immediately upstream of the PDE6A core promoter region. Transient transfection assay in Y79 cells of constructs containing varying lengths of the promoter region showed a decrease in promoter activity with increasing length. The most active segment contained a 177-bp upstream sequence including apparent Crx and Nrl transcription factor binding sites. Both Crx and Nrl transactivated the PDE6A promoter in HEK293 cells and showed a >100-fold increase when coexpressed. Coexpression of a dominant negative inhibitor of Nrl abolished Nrl transactivation but had no effect on Crx. DNase I footprinting assays identified three potential Crx binding sites within a 55-bp segment beginning 29 bp upstream of the transcription start point. Mutation of two of these sites reduced reporter gene activity by as much as 69%. Gel shifts showed that all three Crx sites required a TAAT sequence for efficient binding. Consistent with a requirement for Crx and Nrl in Pde6a promoter activity, Pde6a mRNA is reduced by 87% in the retina of Crx ؊/؊ mice and is undetectable in Nrl ؊/؊ mice at postnatal day 10. These results establish that both Nrl and Crx are required for full transcriptional activity of the PDE6A gene.
The type 6 cGMP phosphodiesterase (PDE6) 1 in rod photoreceptors is a heterotrimeric enzyme that is essential for phototransduction, functioning to lower cytoplasmic cGMP levels in response to light activation of the receptor rhodopsin (1) (2) (3) . The ␣-and ␤-subunits comprise the catalytic core of the enzyme, and the ␥-subunit partially inhibits activity to maintain basal levels in the dark. We have focused our studies on the PDE6A gene, which encodes the ␣-subunit of PDE6. Defects in the coding region of this gene account for a subset of autosomal recessive retinitis pigmentosa (4) . Because all three genes that encode PDE6 subunits are required for subunit assembly (4 -6) , the regulation of gene expression for each subunit could be essential to maximize enzyme production. Dissection of promoter architecture may also be important to develop safe gene therapy vectors with controlled targeted expression in specific cell types. Our initial characterization of the PDE6 ␣-subunit gene promoter indicated that it shows very weak activity compared with other photoreceptor gene promoters including the PDE6B gene promoter (7) . We suggest that the relatively weak expression of this promoter could be useful where overexpression with the well-characterized, most commonly used rhodopsin promoter could induce, rather than reverse, retinal degeneration (8, 9) .
We reported previously that the PDE6A gene promoter is contained within an ϳ4-kb region upstream of the transcription start point, contains several potential cis-elements, and can bind tissue-specific factors in a retinal nuclear extract (10) . A DNase I footprinting region was identified within the first 100 upstream nucleotides that was confirmed by the demonstration of a retina-specific mobility shift. The promoter region was delimited to within a 177-bp upstream region that is active both in vitro (11) and in vivo in transgenic mice (12) . Contained within this region are several potential cis-elements that may bind retina-specific transcription factors including CRX sites (Crx binding element (CBE)) and a non-consensus NRL-like site (Nrl response element (NRE)). CRX binds to the consensus sequence (C or T)TAATC(C or A) (13, 14) and is critical for photoreceptor maturation (15, 16) and expression of many photoreceptor genes in adult retina (14 -18) . NRL is required for normal maturation of rod photoreceptors, as indicated by an Nrl knockout mouse that is devoid of functional rods (19) and patients with cone-rod dystrophy (20) . Nrl binds to the consensus sequence GATGCNTCAGCC and can transactivate rhodop-sin promoter activity synergistically with Crx (14) by physical interaction with Crx (21) . In this paper, we show that the PDE6A promoter is contained within a 100-bp segment of the upstream region and requires Nrl and Crx for full transcriptional activity. Our data and that from studies of the PDE6B gene promoter (7) , which shows greater activity but contains essentially the same binding sites, indicate that promoter strength is at least in part due to the specific sequence and the combinatorial array of cis-elements within a given promoter.
EXPERIMENTAL PROCEDURES
Cell Lines and Cell Culture-Media and antibiotics for tissue culture were purchased from Invitrogen. Fetal bovine serum was purchased from Hyclone. HEK293 and Y79 cells were purchased from American Type Culture Collection and maintained in Dulbecco's modified Eagle's medium supplemented with 5% fetal bovine serum and 100 units/ml penicillin and streptomycin or in RPMI 1640 supplemented with 10% fetal bovine serum.
DNase I Hypersensitivity Assay-Y79 or HEK293 cell nuclei were isolated at 4°C using a nuclei isolation kit (Sigma) following the manufacturers' protocol. The nuclei were pelleted at 2000 rpm in an IEC clinical centrifuge and resuspended in 1ϫ phosphate-buffered saline. Approximately 5 ϫ 10 6 nuclei were digested with DNase I at varying concentrations ranging from 0 to 100 g/ml. The reaction was incubated for 10 min on ice, and reactions were quenched by the addition of EDTA to a final concentration of 25 mM. Genomic DNA was extracted using the DNeasy Tissue Kit (Qiagen). For Southern blot analysis, ϳ15 g of DNA was co-digested with AflII and XhoI at 37°C for 4 h, with one addition of each enzyme after 2 h, and the digestion products were electrophoresed in a 0.7% agarose gel. DNA was transferred to a nylon membrane and hybridized with an [␣- 32 P]dCTP-labeled 3Ј-end probe. The results were visualized by autoradiography after a 5-day exposure.
Generation of Promoter Constructs-The following reporter constructs were used: (a) pGL3-Control encoding the firefly luciferase gene under control of the SV40 strong promoter and SV40 enhancer; and (b) pGL3-Basic containing no promoter and no enhancer. A 4.1-kb XbaI/ XhoI restriction fragment of the upstream region of the PDE6A gene cloned into pBS II KS (10) was amplified with primers U-Sal (5Ј-TTTGTCGACGCTCTGTGCAGACATCTCTTCT-3Ј) and U-Xba (5Ј-AAATCTAGAACCTCCTCTGCTGTCACCT-3Ј), generating a 322-bp segment upstream of the ATG initiation codon. This fragment was cloned into the pBS II KS SmaI site (pBS-322). Eight promoter constructs were made driving luciferase reporter gene expression in the pGL3-Basic plasmid vector. These constructs were called pGL3-260, pGL3-260r (reverse orientation of pGL3-260), pGL3-300, pGL3-592, pGL3-1060, pGL3-1542, pGL3-3800, and pGL3-PL (promoterless). These eight constructs are representative of different lengths of the upstream region of the PDE6A gene. The pGL3-260 and pGL3-260r constructs were prepared by amplification with Pfu polymerase (Stratagene) using U-Sal and U-Xba primers with the pBS-322 vector as template. The PCR product was then cut with StuI, and the 260-bp fragment obtained was cloned into the SmaI site of pGL3-Basic. Forward and reverse orientation was obtained and verified by PCR and restriction digests. The pGL3-300 construct was generated by restriction digest of the pBS-322 plasmid with SalI and NcoI and inserted into the XhoI/NcoI site of pGL3-Basic vector. The pGL3-1060 construct was generated by amplifying a ϳ1279-bp fragment from pBS-4.1 using primers designed to amplify that portion of the upstream region (HAU6-R, 5Ј-GTGCTGGGATTACAGGCGTGAG-3Ј; HARE-3, 5Ј-CTG-TAAATTCTCCTGAAAGTCCCGCAGGAG-3Ј). The product was partially digested with NcoI to obtain a 1060-bp fragment, which was cloned into the SmaI and NcoI sites of pGL3-Basic. The pGL3-3800 was prepared by digesting pBS-4.1 with XbaI and NcoI and cloning the ϳ3.3-kb fragment into the NheI and NcoI sites of pGL3-Basic vector. A ϳ500-bp NcoI to NcoI fragment was then cloned into this intermediate construct to generate the pGL3-3800 construct. The pGL3-593 construct was made by digesting pGL3-3800 with SacI and ApaI and purifying the vector with the insert using a Qiagen gel extraction kit following the manufacturer's protocol. The ends of the vector were filled in using T4 DNA polymerase and blunt-end-ligated together. The pGL3-1542 plasmid was generated by digesting the pGL3-3800 construct with NheI and MluI, followed by purifying the vector with insert using a Qiagen gel extraction kit. The ends of the vector were filled in using T4 DNA polymerase and blunt-end-ligated together. Plasmid preparations were performed using Qiafilter Endofree Maxi or Mega kits (Qiagen) following the manufacturer's recommended protocol. All plasmids were sequenced to verify integrity.
Plasmids containing mutated potential Crx binding sites (TAA to CCG) were generated using mutagenic primers with mutA1-R primer (5Ј-AGAGGGAGCAAGCTTGGGAGACCGAGTCATTAA-3Ј) or mutB-1-R primer (5Ј-AGAGGGAGCAAGCTTGGGAGATTAAGTCACCGATA-TTCTCA-3Ј) using pBS-322 as template and a reverse primer, GL2 (5Ј-ACCTTCTGCGGTTTTTGTATTTC-3Ј). Underlined sequences in the primers indicate mutated sites. Promoter constructs were created from the mutated PCR product from the pBS-322 vector by restriction digests with SalI and NcoI and inserted into the XhoI/NcoI site of pGL3-Basic vector. These promoter constructs are designated pGL3-M13 (m13) and pGL3-M16 (m16), respectively. The plasmids were sequenced to verify mutations. Crx, Nrl, and DD10 expression constructs have been described previously (14, 22) .
Adenofection of Y79 Cells-Y79 cells were transfected using the adenofection method described previously for this cell line (11) . Cells were harvested 48 h after infection and lysed in 100 l of 1ϫ reporter lysis buffer (Promega), and light emission was measured immediately in a Turner Designs 20/20 luminometer (Promega). Values were normalized to viral ␤-galactosidase expression. All experiments were performed in triplicate a minimum of three times (n Ն 9).
Transfection of HEK293 Cells with Calcium Phosphate-HEK293 cells were transfected with calcium phosphate using a standard protocol. Briefly, ϳ6 ϫ 10 5 HEK293 cells were plated in a 60-mm Petri dish in Dulbecco's modified Eagle's medium supplemented with 5% fetal bovine serum and 1% penicillin/streptomycin and grown for 24 -36 h at 37°C to achieve 50 -75% confluence. The medium was changed once, 3 h before transfection. Up to 16 g of DNA in 300 l of 250 M CaCl 2 was combined dropwise with 300 l of 2ϫ Hank's balanced salt buffer and incubated for 30 min. The DNA consisted of 1 g of ␤-galactosidase internal control, 4 -5 g of test plasmid, and 2-5 g of Crx or Nrl expression construct. The DNA mixture was then added dropwise to the cells and incubated for 48 h, with one media change after 12 h of incubation.
Luciferase and ␤-Galactosidase Assays-Cells were harvested and lysed in 350 l of Galacto-Star reporter lysis buffer (Tropix, Inc.), and cell debris was pelleted at 12,000 ϫ g for 2 min at 4°C. For luciferase assays, 20 l of cytosolic extract was diluted to 300 l, and light emission was measured immediately in the luminometer using a luciferase activity kit (Promega) following the suggested protocol. ␤-Galactosidase activity was assayed with the Galacto-Star activity kit (Applied Biosystems) using 20 l of the same cytosolic extract diluted to 300 l. The luminometer was set to 30% (for HEK293 cells) or 40% sensitivity (for Y79 cells), with a delay time of 2 s and an integration time of 10 s. All transfections were done in triplicate a minimum of three times.
DNase I Footprinting of Crx-The plasmid pGL3-300 was used as a template for PCR separately with either sense or antisense radiolabeled primers to generate DNase I footprinting probes. The reaction was performed in binding buffer containing 12.5 mM Hepes, pH 7.6, 100 mM KCl, 5 mM ZnSO 4 , 0.5 mM dithiothreitol, 2% polyvinyl alcohol, and 10% glycerol. Binding reactions were performed on ice for 20 min in a total volume of 50 l including labeled probe and 1ϫ binding buffer with or without 100 ng of purified bovine CrxHD-GST fusion protein (14) . For DNase I digestion, MgCl 2 and CaCl 2 were added to final concentrations of 5 and 2.5 mM, respectively, followed by 0.005, 0.01, or 0.02 unit of DNase I for 1 min at room temperature. The reactions were terminated with 90 l of 1ϫ stop buffer (20 mM EDTA, pH 8.0, 1% SDS, 0.2 M NaCl, and 250 g/ml glycogen). Ten l of 2.5 mg/ml proteinase K was added and incubated at room temperature for 5 min followed by phenol chloroform extraction, precipitation, and resuspension in 1ϫ DNA sequencing gel loading buffer. DNA sequencing reactions were run alongside in a 6% denaturing acrylamide gel.
Electrophoretic Mobility Shift Assay-Gel shift assays were performed essentially as described previously (10), with minor modification. KCl optimum was determined to be 75 mM, and 5% glycerol was included in the reactions. Incubations with and without label were done for 15 min. The binding reaction was run on a nondenaturing 6% acrylamide gel in 0.5ϫ TBE for 2 h at 380 V. CrxHD-GST protein was purified on a glutathione affinity column as previously described (14) Real-time Quantitative PCR-Crx Ϫ/Ϫ mice were obtained from Dr. Connie Cepko (Department of Genetics, Harvard Medical School). The Crx Ϫ/Ϫ mouse was outcrossed to a congenic C57Bl/6 ϫ SJL hybrid strain that is ϩ/ϩ at the rd1 locus (6) . The mice were bred to homozygosity for the Crx knockout allele and maintained for Ͼ6 generations. Total RNA was isolated from the eyes of 10-day-old Crx Ϫ/Ϫ and Nrl Ϫ/Ϫ mice as well as background matched controls using RNAqueous RNA isolation kit (Ambion) or TRIzol (Invitrogen). Reverse transcription reactions (23) were performed with 2 g of total RNA using Moloney murine leukemia virus (Ambion) or Superscript II (Invitrogen) reverse transcriptase following the manufacturer's guidelines. The reaction was diluted to 100 l with water. One l of the diluted cDNA was used in each PCR reaction using either the Dynamo SYBR green qPCR kit (MJ Research) or Platinum Taq polymerase (Invitrogen) with SYBR green I (Molecular Beacons). Primer pairs were used that amplify portions of Pde6a-F (5Ј-CCATGCTGGATGGGATCACTAAC) and PDE6A-R (5Ј-CAGGGT-GACCTCCTCCTTCCTG), Pde6b-F (5Ј-GTATACAAGGAATTTTCTCG) and PDE6B-R (5Ј-CAAATTGCTATAGGCAGAGTCCG), rhodopsin-F (Rho) (5Ј-ATCCCTGAGGGCATGCAATGTTCATG) and Rho-R (5Ј-CT-GCTTGTTCAACATGATGTAGATGAC), and Gapdh-F (5Ј-TGATGA-CATCAAGAAGGTGGTGAAG) and Gapdh-R (5Ј-TCCTTGGAGGC-CATGTAGGCCAT). The reactions were run in the real-time PCR Opticon II system (MJ Research) or iCycler (Bio-Rad) and analyzed using the comparative C t method (⌬⌬C t ) with Gapdh as the normalizer (dorakmt.tripod.com/genetics/realtime.html).
RESULTS
The PDE6A Promoter Region Is in an Open Chromatin State in Y79 Cells-Promoter regions of genes that are transcriptionally active are often demarcated by a DNase I-accessible open chromatin region (24, 25) . Shown in Fig. 1 is the portion of the PDE6A core promoter region analyzed in this study. This region contains three potential Crx binding elements (CBE1-3), one site resembling an Nrl/AP1 binding element (NRE/AP1), and one additional segment that is conserved in the upstream regions of both human and mouse (10) . To assess the chromatin status of the region around the PDE6A promoter region in vivo, a DNase I hypersensitivity assay was performed with Y79 cells, which transcribe PDE6A mRNA (26) . Treatment of intact Y79 nuclei with DNase I revealed two fragments in close proximity (Fig. 2B, lanes 6 and 7) within a 6.4-kb AflII/XhoI genomic fragment spanning the promoter region ( Fig. 2A) . No cleavage products were observed using HEK293 nuclei, which do not express PDE6A (data not shown). The estimated size of these fragments places the hypersensitive sites immediately upstream of the predicted core promoter region. This result is consistent with an active promoter within the region previously identified in vitro (10) .
A 177-bp Segment of the Upstream Region Yields the Highest Reporter Gene Activity in Vitro -To delimit the core promoter region, luciferase reporter gene constructs containing varying lengths of the upstream region were assayed by transient transfection in Y79 Rb cells. Due to the relatively low promoter activity, a modified adenofection method was devised to increase the efficiency of gene transfer severalfold over previously reported methods (11) . As shown in Fig. 3 , the luciferase activity was highest with the shortest fragments tested, pGL3-300 and pGL3-260. Both of these constructs contain 177 bp of sequence extending upstream from the transcription start point and either the entire 5Ј-untranslated region (pGL3-300) or a downstream truncation of 40 bp (pGL3-260), respectively. Reversing the orientation of the pGL3-260 construct (pGL3-260r) reduced activity equivalent to the promoterless control (pGL3-pl). The remaining four constructs tested (pGL3-593, pGL3-1060, pGL3-1542, and pGL3-3800) all contain upstream repetitive elements (10) that appear to attenuate promoter activity. The nucleotide sequence of the upstream region from the transcription start point (ϩ1) to Ϫ105 is shown with annotation of cis-elements that may be of functional significance. All of the putative cis-elements are highly conserved in mouse and rat. A primary focus of this study is on three potential Crx binding sites, CBE-1, CBE-2, and CBE-3. NRE/AP1 is a site similar to Nrl and AP1 binding sites that were shown to be functionally important in rhodopsin and PDE6B promoters (22, 28, 31) . The E-box site was reported to be important for promoter activity in other photoreceptor genes (32) . B, schematic diagram of PDE6A core promoter region. CBE sites are shaded to represent relative binding affinities for Crx determined by gel shift assays in this study. Crx and Nrl Transactivate the PDE6A Promoter-To identify cis-elements necessary for transcriptional activity, we first tested transactivation activity of the photoreceptor-specific transcription factors, Crx and Nrl. Transient transactivation assays were performed in HEK293 cells with and without Crx and Nrl expression constructs. As shown in Fig. 4 , cotransfection of the pGL3-300 PDE6A promoter construct in the absence of Crx or Nrl expression is below detectable limits. In contrast, the inclusion of the Crx or NRL expression construct increased luciferase activity at least 15-20-fold above background levels. Inclusion in the assay of both Crx and Nrl expression constructs further stimulated activity (Ͼ100-fold over background), similar to the synergistic activation of rhodopsin (21) .
Crx Binds within a 55-bp Segment Containing Three Potential Binding Sites-To identify the precise sequence within the PDE6A promoter where Crx binds, DNase I footprinting was done with a purified recombinant Crx fragment containing the DNA binding domain (14) . An extended binding region was observed on both strands of the DNA in the region from Ϫ29 to Ϫ84 (Fig. 5, compare lanes 2 and 3 with lanes 4 and 5) . This region consists of three potential Crx binding sites, all containing a TAAT core consensus Crx binding sequence (see Fig. 1 ) (13, 14) .
Crx Binds More Tightly to CBE-1-The relative binding strength of each potential Crx binding site was determined by electrophoretic mobility shift assay. Eleven double-stranded segments of varying lengths were generated containing various combinations of mutated and intact CBE sites (Fig. 6A) . The shorter oligomers (Fig. 6B, lanes 4 -11) showed comparable labeling with the longer oligomers (lanes 1-3) when electrophoresed for shorter periods of time (data not shown). For each oligomer, the AAT of the core TAAT Crx binding site was mutated to CCG. Mutation of CBE-1 alone (Fig. 6B, lane 11) abolishes binding, in contrast to the significant binding observed with an intact CBE-1 (lane 8) and a longer segment containing all three CBE sites (lane 1). Intact isolated CBE-2 or CBE-3 showed no binding to CBE-2 and only weak binding to CBE-3 (lanes 9 and 10), however, a longer oligomer with CBE-2 and CBE-3 showed strong binding (lane 6), suggesting possible cooperativity of binding or involvement of secondary structure. CBE-3 shows weak binding when included with a mutated CBE-2 site (lane 7). CBE-2, however shows no binding with a mutated CBE-3 site (lane 4), but moderate binding is observed when mutated CBE-1 and CBE-3 sites are included in the oligomer (lane 3). As predicted, mutation of all CBE sites within an oligomer abolishes binding (lanes 2, 5, and 11) , consistent with the requirement for the TAAT core for Crx binding. Each isolated CBE was then tested for binding in the presence of increasing amounts of poly[d(A-T)] (pAT). As shown in Fig. 6C , CBE-1 binding is unaffected even with 3ϫ levels of pAT. Mutation of the CBE-1 TAAT binding core sequence shows nonspecific binding in the absence of pAT (CBE-1m) that is abolished in the presence of pAT. CBE-2 shows very weak binding even in the absence of pAT and is competed completely with 2ϫ pAT. CBE-3 shows intermediate binding strength being competed with 3ϫ pAT (CBE-3, lane 4) . Taken together, the electrophoretic mobility shift assay results show that Crx has the greatest affinity for binding to the CBE-1 site in isola- tion but that the presence of intact CBE-2 and CBE-3 shows binding comparable with CBE-1. These results indicate that DNA bending and cooperativity of binding may be factors in the observed Crx binding.
Crx and Nrl Are Required for Full Promoter Activity in Transfected Cells-The contribution of Crx and Nrl to promoter activity was assessed by site-directed mutagenesis of the TAAT core sequence recognized by Crx and with an Nrl dominant negative expression construct shown to abolish Nrl activity (22) . The Crx core binding sequence TAAT was mutated to CCGT at sites CBE-2 and CBE-3 to generate constructs m13 and m16, respectively. Transient transfection analysis with the normal or mutated sequences in the absence of Crx (Fig. 7A , 300-CRX, m13-CRX, and m16-CRX) showed very low background activity. Mutation of the CBE-2 site (m13ϩCRX) showed a 50% reduction in activity, and mutation of CBE-3 (m16ϩCrx) reduced activity by 69%. Inclusion of the CBE-2 mutant with Crx and Nrl expression constructs (m13ϩCRXϩ NRL) caused a 61% reduction in reporter gene expression, and the CBE-3 mutant with Nrl and Crx (m16ϩCRXϩNRL) caused a 79% reduction compared with the activity seen with the pGL3-300 construct, Crx, and Nrl (300ϩCRXϩNRL). The CBE-3 mutant construct cotransfected with Nrl and Crx reduced reporter gene activity close to the level seen with Nrl alone (300ϩNRL), suggesting that the synergism between Crx and Nrl was abolished. Nrl transactivation of the promoter mutants in the absence of Crx was not significantly different than that observed with the intact promoter (data not shown).
The expression construct DD10 generates a naturally occurring truncated Nrl protein that inhibits Nrl activity (22) . Use of this construct with the pGL3-300 construct and an Nrl expression construct abolished Nrl mediated transactivation (Fig. 7B,  ϩNrl ϩDD10) . Inclusion of all three expression constructs (ϩCrx ϩNrl ϩDD10) reduced promoter activity to a level similar to that seen with Crx alone (ϩCrx), thereby removing the synergistic activation of the promoter.
Crx and Nrl Are Required for Full Transcriptional Activity in in Vivo Knockout
Mouse Studies-To assess the requirement of Nrl and Crx for PDE6A transcription, we determined the relative levels of transcript in Crx (15) and Nrl knockout mouse retinas. Total RNA isolated from whole eyes of postnatal day 10 (PN10) Crx Ϫ/Ϫ and Nrl Ϫ/Ϫ mice and from adult Nrl Ϫ/Ϫ mice was converted to cDNA, amplified with primer pairs that amplify short segments (300 -500 bp) of the coding region of Pde6a, and visualized in real time. Pde6b and Rho were used as positive controls, and Gapdh was used for normalization. In the Crx Ϫ/Ϫ mouse, Pde6b and Rho transcript levels were reported to be at 75% and 8%, respectively, of the levels observed in Crx ϩ/ϩ littermates (15) . As shown in Fig. 8 , the mRNA levels of Pde6a, Pde6b, and rhodopsin in the Crx knockout mice were 13%, 55%, and 11%, respectively, of that observed in the Crx ϩ/ϩ littermates. Thus, Crx is necessary to achieve wild type transcription levels. In contrast, of the three genes analyzed, only rhodopsin was barely detectable in the PN10 retina of Nrl knockout mice, suggesting that Nrl may be essential for transcription of the Pde6a and Pde6b genes. Surprisingly, Pde6a (7% of wild type level) and, to a lesser extent, Pde6b (2% of wild type level) mRNA were detected in the adult retina of Nrl knockout mice. Determining the mechanism for this observation will require further study. Together, these reverse transcription-PCR results indicate that both Crx and Nrl are required in vivo for full transcriptional activity of the Pde6a gene.
DISCUSSION
Whereas several photoreceptor gene promoters have been analyzed in vitro and outside of the native promoter context in transgenic mice, in none of these studies have the data been confirmed in vivo in the native promoter. Using the DNase I hypersensitivity assay in Y79 cell nuclei, we found a strong correlation with the location of the minimal promoter delimited by the in vitro analysis. In addition to the primary DNase I hypersensitive sites, we also consistently observed a slower migrating, very weak signal that maps further upstream, indicating another possible open chromatin regulatory region. Because Rb cells represent a mixed population of cells, this region may contain a binding site active in cells not entered into a photoreceptor commitment pathway to act as a negative regulator of transcription.
An unusual feature of the PDE6A promoter relative to other photoreceptor promoters studied to date is the presence of numerous repetitive elements in close proximity, beginning ϳ900 bp from the transcription start point. The presence of these elements seems to attenuate gene expression and at least partly explains why promoter activity decreases with increasing length of the promoter. It also suggests that no other positive cis-elements are likely to be found within at least 3800 bp of the upstream region.
Our Crx reverse transcription-PCR data, coupled with previously published data (15) , average to a 38% reduction of Pde6b mRNA, and we found an 87% reduction in Pde6a mRNA, indicating a critical role for Crx in achieving full promoter activity of both the Pde6a and Pde6b promoters. This is in contrast to other published results suggesting that Crx does not have a significant involvement in the activation of the Pde6b promoter (27, 28) . This result is based on data from transient transfection assays showing that Nrl and Sp4 did transactivate the promoter but that Crx or combinations of Crx with Nrl or Sp4 did not, and on the lack of effect upon introduction of the promoter with a mutated CRE in both Y79 and Xenopus embryo transient transfections. This could reflect a difference between the native environment of the promoter within chromatin as in the Crx knockout mice compared with the artificial environment created with transient or stable transfections. Alternatively, the discrepancy in results may be resolved by a recent preliminary study (33) showing that inclusion of Crx with Nrl and Sp4 showed a greater stimulation of Pde6b promoter activity than did Nrl and Sp4 together without Crx. This concurs with a requirement for Crx for full activity of the Pde6a and Pde6b promoters.
In the absence of Nrl, there is no detectable Pde6a mRNA at PN10; however, a weak signal is detected in the adult mouse, based on microarray analysis and real-time reverse transcription-PCR. These data are consistent with Affymetrix microarray analysis showing that Pde6a turns on after PN4 and before PN8 (www.scripps.edu/cb/friedlander/gene_expression/search. html, Affy# 100696_at). The cellular origin of the transcripts, however, at any given time point has not been determined. Despite the presence of rudimentary discs contained within shortened outer segments, the Nrl Ϫ/Ϫ mouse displays very low to no expression of several rod photoreceptor-specific markers including Pde6b (19) . It seems most likely that the Pde6a signal detected in Nrl-null mice is from inner retinal cells, consistent with our previous report showing in situ hybridization labeling in the inner nuclear layer of adult mouse retina (12) .
Comparison of the anatomy of the Pde6a and Pde6b promoters reveals a striking similarity. Both core promoters are contained within 105 bp upstream of the transcription start point, both initiate transcription at one major site and one minor site, and both consist of a similar array of cis-elements including a GC box, an E-box, and Crx and Nrl binding sites, yet there is a 5-8-fold lower activity of the Pde6a promoter (7, 11) . The primary differences are the spatial arrangement of the ciselements, the sequence of the NRE/AP1 site, and the absence of repetitive elements upstream of the Pde6b promoter. We have found that the difference in promoter activities can be accounted for by the repetitive elements and the NRE/AP1 sequence. Conversion of the Pde6a AP1 sequence to that of Pde6b and removal of the repetitive elements raise the activity of Pde6a to the level of Pde6b. 2 We also found that the position of the cis binding sequence is critical for promoter activity. Moving the Pde6b NRE/AP1 site further upstream did not elevate Pde6a activity. These results and the results reported here indicate that there is a direct correlation between the spatial array of cis-elements and promoter strength. Thus, it may be possible to develop a series of promoters with defined strengths simply by rearranging the same cis-elements, a hypothesis that is worth testing for the development of safe, predictable vehicles for gene therapy.
Our results show that of three CBE binding sites in the Pde6a promoter, a site that is overlapping with the NRE/AP1-like site (CBE-1) binds Crx very tightly in isolation; however, DNase I footprinting, transient transfection assays, and gel 2 J. B. White and S. J. Pittler, unpublished observations. FIG. 6. Gel shift assays of Crx binding to CBE sites in the PDE6A promoter. A, oligomers used for gel shift assays. Eleven double-stranded oligomers were synthesized according to the sequence of the human PDE6A promoter region of varying lengths and containing different combinations of intact and mutated CBE sites. The positions of the CBE sites and the predicted Nrl binding site are shown below the sequences. Mutated residues are boxed and shaded. B, Crx binding to intact and mutated CBE. Binding reactions were performed in the presence of 2ϫ pAT and electrophoresed through nondenaturing polyacrylamide gels. All of the shorter unshifted probes that ran off the gel (lanes 4 -11) were observed in a shorter run (data not shown). C, CBE-1 in isolation shows the highest relative binding affinity. Binding assays were performed in the presence of increasing amounts of pAT (0, 1ϫ, 2ϫ, and 3ϫ) for each of the isolated CBE sequences and a mutated CBE-1. CBE-1 binding was unaffected at even the highest level of competitor (CBE-1, lane 4).
shift assays indicate that the CBE-2 and CBE-3 sites together can also show strong binding. The close proximity of Nrl and Crx could promote protein-protein interaction that has been demonstrated with these factors (21) . The gel shift assay result in which CBE-1 and CBE-2 show weak binding in isolation (Fig. 6A, lanes 9 and 10) but relatively strong binding at each site when the sites are combined (lanes 3, 6, and 7) is seemingly contradictory to the other binding data with CBE-1. The data are consistent, however, with a requirement for defined DNA bending and possible cooperativity of Crx binding. Also consistent with this idea is our previous finding using human retina nuclear extracts in gel shift assays, in which a retina-specific shift was only observed when the entire promoter region was included in the probe (10) . The rhodopsin proximal promoter region is composed of a very similar array of cis-elements with an NRE flanked on both sides by Crx binding sites (29) , and this promoter also shows weak activity in the absence of an upstream enhancer (30) . Overall, the data indicate that binding of Crx to all three CBE sites, Nrl binding to the NRE/AP1 site, and presumably the basal transcription machinery are required for full activation of the Pde6a promoter.
